This HTML5 document contains 71 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n10http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q59529981
rdf:type
wikibase:Item
schema:description
im April 2012 veröffentlichter wissenschaftlicher Artikel wetenschappelijk artikel article by Anne K. Pagsberg et al published April 2012 in Schizophrenia Research наукова стаття, опублікована у квітні 2012 article scientifique publié en 2012
p:P577
wds:Q59529981-CC8F5DB2-C2D8-458C-AC0C-6DA472590253
wdt:P577
2012-04-01T00:00:00Z
p:P407
wds:Q59529981-F5A3D6B7-9B05-484E-82CE-BA6F7CB9B05F
wdt:P407
wd:Q1860
p:P2093
wds:Q59529981-E22CD475-A5ED-4AD7-A2BE-5E9026277AD6 wds:Q59529981-D3C56EB0-49D2-423D-BAD5-65ABD8F95744 wds:Q59529981-2E72CB37-C9B4-4C68-BACD-D28C261ABD66 wds:Q59529981-2841E969-22B1-4443-AF55-206078A6B8CA wds:Q59529981-22B8FD8C-551A-41BB-A480-27B7B1602C8A wds:Q59529981-18475EB7-D6FB-4EA5-AB36-C2BCBA35140F wds:Q59529981-854A7C0F-E68A-46FB-93EC-E7195722411D wds:Q59529981-68F84CF3-6A13-486E-829C-3010F7F66609 wds:Q59529981-60AAF07F-A4DA-4A0C-987F-41FFE180BAF6 wds:Q59529981-B66C736B-7998-45F2-BC45-41F9064A4FA1 wds:Q59529981-A52C7BAC-4F22-4BB9-8F07-67BD9D568E8E wds:Q59529981-A129D055-8114-4A20-A5A5-1128C5C6C428
wdt:P2093
Christoph U. Correl Karsten G. Jensen Ditte Rudaa Marie Stentebjerg-Olesen Anders Fink-Jensen Torben S. Carlsen Christian Gluud Niels Bilenberg Ann-Sophie Saldeen Jens R. Jepsen Pia Jeppesen Peter Jantzen
rdfs:label
Poster #64 RECRUITMENT STATUS OF THE TEA TRIAL: TOLERANCE AND EFFECT OF ANTIPSYCHOTICS IN CHILDREN AND ADOLESCENTS WITH PSYCHOSIS. AN INVESTIGATOR-INITIATED, PHASE IV, RANDOMISED DOUBLE-BLIND MULTI-CENTRE TRIAL OF THE BENEFITS AND HARMS OF ARIPIPRAZO Poster #64 RECRUITMENT STATUS OF THE TEA TRIAL: TOLERANCE AND EFFECT OF ANTIPSYCHOTICS IN CHILDREN AND ADOLESCENTS WITH PSYCHOSIS. AN INVESTIGATOR-INITIATED, PHASE IV, RANDOMISED DOUBLE-BLIND MULTI-CENTRE TRIAL OF THE BENEFITS AND HARMS OF ARIPIPRAZO
skos:prefLabel
Poster #64 RECRUITMENT STATUS OF THE TEA TRIAL: TOLERANCE AND EFFECT OF ANTIPSYCHOTICS IN CHILDREN AND ADOLESCENTS WITH PSYCHOSIS. AN INVESTIGATOR-INITIATED, PHASE IV, RANDOMISED DOUBLE-BLIND MULTI-CENTRE TRIAL OF THE BENEFITS AND HARMS OF ARIPIPRAZO Poster #64 RECRUITMENT STATUS OF THE TEA TRIAL: TOLERANCE AND EFFECT OF ANTIPSYCHOTICS IN CHILDREN AND ADOLESCENTS WITH PSYCHOSIS. AN INVESTIGATOR-INITIATED, PHASE IV, RANDOMISED DOUBLE-BLIND MULTI-CENTRE TRIAL OF THE BENEFITS AND HARMS OF ARIPIPRAZO
schema:name
Poster #64 RECRUITMENT STATUS OF THE TEA TRIAL: TOLERANCE AND EFFECT OF ANTIPSYCHOTICS IN CHILDREN AND ADOLESCENTS WITH PSYCHOSIS. AN INVESTIGATOR-INITIATED, PHASE IV, RANDOMISED DOUBLE-BLIND MULTI-CENTRE TRIAL OF THE BENEFITS AND HARMS OF ARIPIPRAZO Poster #64 RECRUITMENT STATUS OF THE TEA TRIAL: TOLERANCE AND EFFECT OF ANTIPSYCHOTICS IN CHILDREN AND ADOLESCENTS WITH PSYCHOSIS. AN INVESTIGATOR-INITIATED, PHASE IV, RANDOMISED DOUBLE-BLIND MULTI-CENTRE TRIAL OF THE BENEFITS AND HARMS OF ARIPIPRAZO
p:P50
wds:Q59529981-7618EE87-C23E-4DB4-864A-512F073C9754 wds:Q59529981-2D0A1F40-A217-4EF3-90A9-128CDA841375 wds:Q59529981-F62DCAB7-C82E-4362-80C4-51A731F42B28 wds:Q59529981-D8716959-0DF9-46EF-A2E7-1F4C82EDCE7B
wdt:P50
wd:Q90195048 wd:Q40274772 wd:Q90569587 wd:Q29122092
p:P1476
wds:Q59529981-128BBA98-1904-4E11-92F4-83667D6AADE9
wdt:P1476
Poster #64 RECRUITMENT STATUS OF THE TEA TRIAL: TOLERANCE AND EFFECT OF ANTIPSYCHOTICS IN CHILDREN AND ADOLESCENTS WITH PSYCHOSIS. AN INVESTIGATOR-INITIATED, PHASE IV, RANDOMISED DOUBLE-BLIND MULTI-CENTRE TRIAL OF THE BENEFITS AND HARMS OF ARIPIPRAZO
p:P304
wds:Q59529981-27A3CC6A-6FB4-4DFA-89DB-535617F1EF23
wdt:P304
S208
p:P31
wds:Q59529981-9B418A00-6D6C-4777-A3DA-25BE7D578717
wdt:P31
wd:Q13442814
p:P921
wds:Q59529981-E30EE43A-0E54-4E01-A5EE-613D82AEBD07 wds:Q59529981-B29A9BDC-CF6D-40A6-AF53-782FC5852970 wds:Q59529981-7CED0694-D8CF-4F86-908F-AB33C10232DC wds:Q59529981-45C04E48-8C55-48B1-8C36-EE2BBB2EF216 wds:Q59529981-404a1966-4faf-3c62-3bd9-1c8889049ead
wdt:P921
wd:Q1492760 wd:Q76649493 wd:Q42825046 wd:Q41112 wd:Q2706176
p:P1433
wds:Q59529981-578054FF-259D-46FC-BB38-936DC83EA30C
wdt:P1433
wd:Q7431607
p:P478
wds:Q59529981-8D09A0EE-D6BF-4E01-AA3E-5A8CFE15F1DC
wdt:P478
136
p:P356
wds:Q59529981-BB3134E4-74EE-40A8-B685-5B55C7891C93
wdtn:P356
n10:S0920-9964(12)70636-9
wdt:P356
10.1016/S0920-9964(12)70636-9